Pharmacotherapy Specialty Review Course for Recertification, Core Therapeutic Modules + RECERT EXAMS Package (Cert # L219218)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 10/27/2021
Content Release Date: 11/24/2021
Expiration Date: 11/22/2022
Activity Type: Application-based
CE Credits: 21.25 (BPS and ACPE) contact hours
Activity Fee: $475 (ASHP member); $675 (non-member)

Activity Overview

This course is intended for BCPSs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

  • Review pertinent clinical topics and practice skills
  • List valuable resources for further self-study  

This online course consists of 15 activities (see table below) and provides up to 21.25 contact hours of continuing pharmacy education credit and/or recertification credit.

The home study review course will be available on February 2, 2022.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in pharmacotherapy.

Board certified pharmacists are eligible to receive up to 21.25 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment. 

This course is not intended for those preparing to take the BPS Pharmacotherapy Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ptherapy-review 

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS. 

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

The review course for recertification consists of 10 activities (see table below). In each activity, faculty review clinical topics and practice skills using a case-based approach. This package is intended for board certified pharmacists in need of recertification credit; the activities were designed based on the content outline developed by the Board of Pharmacy Specialties (BPS).

Learning Activity

ACPE Number

Contact Hours

Cardiovascular Disease: Primary Prevention Case

0204-0000-21-613-H01-P

1.50 ACPE

Cardiovascular Disease: Secondary Prevention Case

0204-0000-21-614-H01-P

1.50 ACPE

Complex Heart Failure Case

0204-0000-21-615-H01-P

1.50 ACPE

Providing Safe and Effective Pharmacotherapy:
 Key Regulatory and Quality Approaches

0204-0000-21-616-H05-P

1.50 ACPE

  →   Recertification Assessment: Group 1 (TBD passing score required)

6.0 BPS

Research Methods and Data Analysis / Evidence-based Practice and Resources

0204-0000-21-617-H04-P

2.50 ACPE

Oncology and Supportive Care Case

0204-0000-21-618-H01-P

1.50 ACPE

Complex Nursing Home Patient Case

0204-0000-21-619-H01-P

1.50 ACPE

  →   Recertification Assessment: Group 2  (TBD passing score required)

5.5 BPS

Complex HIV/AIDS Case

0204-0000-21-620-H02-P

1.50 ACPE

Complex Pediatric Asthma Case

0204-0000-21-621-H01-P

1.75 ACPE

Complex Pneumonia Case

0204-0000-21-622-H01-P

1.50 ACPE

  →  Recertification Assessment: Group 3 (TBD passing score required)

4.5 BPS

After participating in this CPE activity, learners should be able to:

Cardiovascular Disease: Primary Prevention Case
ACPE #: 0204-0000-21-613-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including hypertension, dyslipidemia, chronic kidney disease, diabetes, and obesity.
  • State the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommendations for adult immunizations.
  • Determine how to advise a patient on point-of-care testing to measure response to drug therapy.
  • Discuss national benchmarking standards and implications to patient care. 

Cardiovascular Disease: Secondary Prevention Case
ACPE #: 0204-0000-21-614-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including atrial fibrillation (AF), acute coronary syndromes (ACS), and gastroesophageal reflux disease (GERD).
  • Develop a plan to address continuity of care issues.
  • Formulate a medication therapy plan for smoking cessation.
  • Determine how to manage drug – drug and drug-induced disease interactions in a patient with ischemic heart disease.
  • Discuss quality of life in this population.
  • Discuss national benchmarking standards and implications to patient care. 

Complex Heart Failure Case
ACPE #: 0204-0000-21-615-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with multiple conditions, including heart failure, electrolyte disturbances in acute decompensated heart failure, diabetes, and a thyroid disorder.
  • Discuss the medications that should be avoided in heart failure.
  • Identify safety issues in this population.
  • Define inadequate health literacy in this population.

Providing Safe and Effective Pharmacotherapy: Key Regulatory and Quality Approaches
ACPE #: 0204-0000-21-616-H05-P

  • Explain the regulatory and accreditation requirements of a comprehensive medication use program.
  • Describe methods to develop and maintain a medication use system.
  • Discuss technology used to promote safe and effective medication use.
  • Apply national regulations and evidence-based practices for medication safety and quality.
  • Interpret results from pharmacotherapy-related quality improvement activities. 

Research Methods and Data Analysis / Evidence-based Practice and Resources
ACPE #: 0204-0000-21-617-H04-P

  • Analyze biomedical literature with regard to study methodology, statistical analysis, and significance.
  • Explain the use of evidence-based treatment guidelines and protocols.
  • Interpret the biomedical literature and its application to clinical practice.
  • Identify sources of information to use to answer questions in one’s practice, or from patients and healthcare professionals.
  • Explain how to provide education regarding evidence-based practice to current and future health care professionals. 

Oncology and Supportive Care Case
ACPE #: 0204-0000-21-618-H01-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including breast cancer, febrile neutropenia, and pulmonary embolism.
  • Compare and contrast current breast cancer screening recommendations.
  • Develop a plan to manage pain and nausea/vomiting in a patient with cancer.
  • Discuss safety issues in this population.
  • Discuss adherence issues with oral chemotherapy regimens.

Complex Nursing Home Patient Case
ACPE #: 0204-0000-21-619-H01-P

  • Select the appropriate treatment for a complex patient-case with multiple conditions, including stroke, depression/anxiety, dementia, chronic obstructive pulmonary disease (COPD) management, osteoarthritis, osteoporosis, and pain.
  • Discuss complementary/alternative medicine and safety issues in this population.
  • Discuss quality improvement initiatives and regulations in the nursing home setting. 

Complex HIV/AIDS Case
ACPE #: 0204-0000-21-620-H02-P

  • Select the appropriate treatment and monitoring of a complex patient-case with multiple conditions, including dyslipidemia, and hepatitis B.
  • Identify and manage common drug interactions experienced by HIV-treated patients.
  • Identify and manage common adverse drug reactions experienced by HIV-treated patients.
  • Determine appropriate medication choices for the treatment and prevention of common opportunistic infections.
  • Discuss quality of life issues in terms of medication therapy for HIV-infected patients.
  • Identify and recommend appropriate resource organizations/groups to assist a specific patient. 

Complex Pediatric Asthma Case
ACPE #: 0204-0000-21-621-H01-P

  • Select optimal treatment and monitoring for a complex patient-case with acute asthma exacerbation, acute otitis media, and seasonal allergies.
  • Apply methods for counseling a patient and/or caregiver in asthma self-management with comprehensive documentation of the patient counseling.
  • Develop a plan for childhood vaccinations in a child who has been delayed in receiving them.
  • Implement principles of shared-decision making and culturally effective care when using complementary/alternative medicine in a pediatric patient. 

Complex Pneumonia Case
ACPE #: 0204-0000-21-622-H01-P

  • Select the appropriate treatment and monitoring for a complex patient-case with multiple conditions, including pneumonia, acute renal insufficiency, sepsis, chronic obstructive pulmonary disease (COPD), and dehydration.
  • Interpret clinical data, including lab, physical examination and vital signs.
  • Determine and prioritize pneumonia-related treatment goals.
  • Determine approaches to manage drug allergies and select next best drug therapy when primary drugs are precluded.
  • Discuss approaches to limiting antimicrobial over use by stewarding antibiotic usage appropriately.
  • Discuss safety issues in patients receiving treatment for pneumonia.

The Core Therapeutic Modules for Recertification Package consists of 5 activities (see table below). In each activity, faculty review clinical topics and practice skills using a case-based approach. This package is intended for board certified pharmacists in need of recertification credit; the activities were designed based on the content outline developed by the Board of Pharmacy Specialties (BPS).

Learning Activity

ACPE Number

Contact Hours

Select Topics in Psychiatric Disorders

0204-0000-21-625-H01-P

1.00 ACPE

Select Topics in Rheumatology

0204-0000-21-626-H01-P

1.00 ACPE

Heart Failure

0204-0000-21-627-H01-P

1.00 ACPE

Selected Topics in Renal Disease

0204-0000-21-628-H01-P

1.00 ACPE

Patient Education and Health Literacy

0204-0000-21-629-H04-P

1.00 ACPE

  →   Recertification Assessment: Core Therapeutic Modules (77% passing score required)

5.00 BPS

 

After participating in these CPE activities, learners should be able to:

Select Topics in Psychiatric Disorders
ACPE #: 0204-0000-21-625-H01-P
For patients with bipolar, schizophrenia, anxiety disorders, post-traumatic stress disorder, and/or substance abuse disorder:

  • Interpret basic diagnostic factors, clinical presentation, and target symptoms of selected psychiatric disorders.
  • Formulate the most appropriate treatment, monitoring, and follow-up plans based on patient-specific information and current guidelines.
  • Evaluate drug-related problems and response to therapy. 

Select Topics in Rheumatology
ACPE #: 0204-0000-21-626-H01-P
For patients with rheumatoid arthritis, osteoarthritis and gout:

  • Formulate the most appropriate treatment and monitoring, based on drug-specific variables, patient-specific information and clinical practice guidelines.
  • Evaluate drug-related problems and response to therapy.
  • Recommend appropriate modifications of patient-specific treatment plans based on follow up assessment. 

Heart Failure
ACPE #: 0204-0000-21-627-H01-P

  • Interpret diagnostic and/or laboratory tests, vital signs and clinical presentation in patients with heart failure.
  • Formulate the most appropriate treatment and monitoring plans, based patient-specific information and current guidelines for patients with heart failure.
  • Recommend appropriate modifications of patient-specific treatment plans based on follow up assessment in patients with heart failure. 

Selected Topics in Renal Disease
ACPE #: 0204-0000-21-628-H01-P

  • For patients with acute kidney injury and chronic kidney disease determine the most appropriate treatment and monitoring based on drug characteristics, patient-specific factors, and current clinical practice guidelines.
  • Manage drug dosing and drug-related complications in patients receiving renal replacement therapy.
  • Identify appropriate modifications to the treatment plans based on follow-up assessment to optimize outcomes. 

Patient Education and Health Literacy
ACPE #: 0204-0000-21-629-H04-P

  • Assess considerations for communicating pharmacotherapy plans to various patient populations, including pediatric patients and geriatric patients, using universal health literacy precautions.
  • Evaluate methods for educating patients and caregivers on safe and appropriate use of medications and devices.

Faculty bios

Christopher Betz, Pharm.D., BCPS, FKSHP, FASHP*
Professor
Sullivan University College of Pharmacy and Health Sciences
Cardiology Clinical Pharmacy Specialist
Jewish Hospital Rudd Heart & Lung Center – U of L Health
Louisville, Kentucky 

Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC*
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Kalin Clifford, Pharm.D., BCPS, BCGP
Associate Professor of Pharmacy Practice, Division of Geriatrics and Pediatrics
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy
Advanced Practice Pharmacist/Clinical Pharmacy Specialist, Geriatrics & Extended Care
VA North Texas Health Care System
Dallas, Texas 

Ilya Danelich, Pharm.D., BCPS, BCCP
Clinical Coordinator; Cardiology Clinical Pharmacy Specialist
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 

Jessica Farrell, Pharm.D.
Associate Professor
Albany College of Pharmacy and Health Sciences
Clinical Pharmacist
The Center for Rheumatology
Albany, New York 

Stuart T. Haines, Pharm.D., BCPS, BCACP, FASHP
Professor and Director
Professional Development
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Meredith Keisler, Pharm.D., BCOP, CPP
Clinical Pharmacist Practitioner - Oncology Palliative Care
UNC Health
Chapel Hill, North Carolina 

Patricia C. Kienle, B.S.Pharm., MPA, BCSCP, FASHP
Director, Accreditation and Medication Safety
Cardinal Health
Wilkes-Barre, Pennsylvania 

Mei T. Liu, Pharm.D., BCPP
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Psychiatry Clinical Pharmacist
Penn Medicine Princeton House Behavioral Health
Princeton, New Jersey 

Jill Morgan, Pharm.D., BCPS, BCPPS
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland 

Nicholas Owens, Pharm.D., BCACP, BCPS
Assistant Professor of Clinical Pharmacy
Philadelphia College of Pharmacy at University of the Sciences
Philadelphia, Pennsylvania 

Marc H. Scheetz, Pharm.D., M.Sc., BCPS-AQID, FCCP
Professor of Pharmacy and Pharmacology; Director of Pharmacometrics Center of Excellence
Midwestern University
Downers Grove, Illinois
Infectious Diseases Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois

Douglas Slain, Pharm.D., BCPS, AQ-ID*
Professor and Infectious Diseases Clinical Specialist
West Virginia University
Morgantown, West Virginia 

Laura Waite, Pharm.D., BCPS, CLS, BC-ADM
Associate Professor of Clinical Pharmacy, Director of Student Recruitment and Engagement
Middle States Commission on Higher Education Self-Study Co-Chair
Philadelphia College of Pharmacy
University of the Sciences
Philadelphia, Pennsylvania 

Kristin Watson, Pharm.D., BCCP
Associate Professor
University of Maryland
School of Pharmacy
Baltimore, Maryland 

*Content Matter Experts

Anna M. Jackson, Pharm.D., BCPS
Tony Martin, Pharm.D., M.B.A.
Susan R. Dombrowski, M.S., R.Ph.

CORE THERAPEUTIC MODULES

Iman Aberra, BCPS
Mohammad Qasim Adil, Pharm.D., BCPS
Junsup (Justin) Ahn, Pharm.D., BCPS
Dawn Anderson, Pharm.D., M.B.A., BCPS
John Austin, Pharm.D., BCPS, BCCCP
Jill Balcombe, Pharm.D., BCPS
Grace Benson, Pharm.D., BCPS
Ethan Blashford, Pharm.D., BCPS
Christina Brummett, Pharm.D., BCPS, BCCCP
Carley Castelein, Pharm.D., BCPS, CPPS
Hetty Cheng, Pharm.D., BCPS
Kevin Chilbert, Pharm.D., BCPS
Lauren Dombrowski, Pharm.D., BCPS
Janine Douglas, Pharm.D., BCPS
Shannon Eidsness, Pharm.D., BCPS
Karly Erickson, Pharm.D., BCPS, BCCCP
Michelle Estevez, Pharm.D., DPLA, BCPS
David Evans, Pharm.D., BCPS
Katherine Evans, Pharm.D., BCPS
Christopher  Garner, B.S.Pharm., BCPS
Carmen Gust, Pharm.D., BCPS
Matt Haldiman, Pharm.D., MBA, BCPS
Coleen Hart, Pharm.D, BCPS, BCCCP
Chris Hayek, Pharm.D., BCPS
Destine Hoover, Pharm.D., BCPS
Jean Huang, Pharm.D., BCPS
James Hummel, Pharm.D., BCPS, CBIS
Kamanski Jordan-Williams, Pharm.D., BCPS
Lairyn Kenney, BS, Pharm.D., BCPS
Eric Kinney, Pharm.D., BCPS
Yvonne  Labram, Pharm.D., BCPS
Jane LeBlond, Pharm.D.
Jennifer Lee, Pharm.D., BCPS, BCCCP
Linda Logan, Pharm.D., BCPS, BCPP, BCACP
Kenzi Lopes-Pimental, Pharm D., BCPS
Erin Mangum, Pharm.D., BCPS
Samuel Martin, Pharm.D., BCPS
Amanda Memken, Pharm.D., BCPS, BCPPS
Clarice Montgomery, Pharm.D. BCPS
Charu Narra, Pharm.D., BCPS
Debra Oliver, Pharm D., BCPS
Monica Owen, Pharm.D., BCPS
Jennifer Panic, Pharm.D., BCPS
Tyler Perry, Pharm.D., BCPS
Kathy Pollitzer, Pharm.D., BCPS
Amina Popoola, Pharm.D., BCPS
Rebecca Powell, Pharm.D., BCPS
Forrest Ridgway, Pharm.D., BCPS, BCOP
Alex Rock, Pharm.D., AAHIVP, BCPS
Kristen Rychalsky, Pharm.D., BCPS, BCOP
Nahirony Sanchez Coronado, Pharm.D., BCPS, BCGP
Aulia Shariat, Pharm.D., BCPS
Caroline Simari, Pharm.D., BCPS
Donald Singh, Pharm.D., MBA, BCPS
Pauline Situ, Pharm D., BCPS
Mehek Talwar, Pharm.D., BCPS
Amanda Troup, Pharm.D., BCPS
Cortney  Valela , Pharm.D. BCPS
Sarah White, Pharm.D., BCPS
Brittany Williams, Pharm.D., BCPS
Lauren Williams, Pharm.D., BCPS
Angela Wowczuk, Pharm D., BCPS, AAHIVE
Kristen Young, Pharm.D., BCPS
Cella Yung, Pharm.D., BCPS, CDCES
Katrina Zywiec, Pharm.D., BCPS

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Patricia Kienle: Cardinal Health/Employee; CriticalPoint LLC/Instructor; USP/Volunteer; ASHP/Author
  • Marc Scheetz: Merck/Grant to MWU; Abbvie/Consulting; Supertrans Medical/Consulting and Contracts; Nevakar/Consulting and Contracts; Allecra/Contract
  • Jessica Farrell: Pfizer, speaker bureau; Abbvie, speaker bureau; Cumberland Pharmaceuticals, consultant

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.